Sinopharm CNBG COVID-19 vaccine
From Wikipedia, the free encyclopedia
Jump to navigation
Jump to search
Vaccine against COVID-19
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Protein subunit |
Clinical data | |
Routes of administration | Intramuscular |
Legal status | |
Legal status |
Sinopharm CNBG COVID-19 vaccine is a COVID-19 vaccine developed by China National Biotec Group (CNBG), a subsidiary of Sinopharm.[1][2]
They claim to be the world's first "second generation" protein recombination vaccine.[3]
References[edit]
- ^ "Emergency use of Sinopharm's new CNBG protein vaccine approved in UAE". Gulf News. 27 December 2021. Retrieved 27 December 2021.
- ^ "China's new recombinant COVID-19 vaccine starts human tests". Xinhua. 25 April 2021. Retrieved 5 May 2021.
- ^ 國藥集團:二代重組蛋白新冠疫苗保護效果良好
Scholia has a profile for Sinopharm CNBG COVID-19 vaccine (Q110291641). |
Development | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Classes | |||||||||||
Administration | |||||||||||
Vaccines |
| ||||||||||
Inventors/ researchers | |||||||||||
Controversy | |||||||||||
Related | |||||||||||
|
This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it. |
This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |
Hidden categories:
- Articles with short description
- Short description matches Wikidata
- Use dmy dates from December 2021
- Drugs with non-standard legal status
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Articles containing unverified chemical infoboxes
- Drugs that are a vaccine
- All stub articles